Helios Clinical

Helios Clinical Research is an integrated clinical site organization (IRO) that partners with patients, physicians, and biopharmaceutical sponsors to optimize the clinical trial process. Launched in 2022 by the private equity firm Grant Avenue Capital, the company operates a network of over 20 clinical research sites across the United States, with a significant presence in Texas, Florida, Tennessee, and Ohio. Helios specializes in a wide range of therapeutic areas, including oncology, vaccines, metabolic disorders, urology, and dermatology. By centralizing operations and leveraging a world-class clinical development team, the company aims to accelerate drug approval timelines through efficient patient recruitment, regulatory compliance, and high-quality data collection.